The pharmacokinetics and pharmacodynamics of TAK-442, an oral, direct factor Xa inhibitor following multiple dosing in healthy male subjects

被引：0
|
作者：
Stringer, Fran [1 ]
Scott, Graham [1 ]
Kupfer, Stuart [2 ]
Prescott, Kim [1 ]
Jenkins, Robert [1 ]
Harding, Sarah [1 ]
Cao, Charlie [2 ]
Kawamura, Masaki [2 ]
机构：
[1] Takeda Global Res & Dev Ctr Ltd Europe, London, England
[2] Takeda Global Res & Dev Inc, Lake Forest, IL USA
来源：
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY | 2010年 / 70卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：305 / 305
页数：1
相关论文
共 50 条
  • [1] Evaluation of interethnic differences in the pharmacokinetics and pharmacodynamics of TAK-442, a novel factor Xa inhibitor, in healthy male Japanese and European subjects
    Okamoto, H.
    Stringer, F.
    Hirayama, M.
    Nakamura, K.
    Nakata, E.
    Minamide, Y.
    Kawamura, M.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2011, 9 : 107 - 108
  • [2] PHARMACODYNAMIC INTERACTION BETWEEN TAK-442, AN ORAL DIRECT FACTOR XA INHIBITOR, AND PRASUGREL IN HEALTHY SUBJECTS
    Wood, Nolan
    Stringer, Fran
    Wu, Ruishan
    Kawamura, Masaki
    Spaeder, Jeff
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2011, 57 (14) : E1504 - E1504
  • [3] Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939 - an oral, direct Factor Xa inhibitor - after multiple dosing in healthy male subjects
    Kubitza, D
    Becka, M
    Wensing, G
    Voith, B
    Zuehlsdorf, M
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2005, 61 (12) : 873 - 880
  • [4] Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939—an oral, direct Factor Xa inhibitor—after multiple dosing in healthy male subjects
    Dagmar Kubitza
    Michael Becka
    Georg Wensing
    Barbara Voith
    Michael Zuehlsdorf
    European Journal of Clinical Pharmacology, 2005, 61 : 873 - 880
  • [5] Comparison of the pharmacokinetics and pharmacodynamics of TAK-442, a novel factor Xa inhibitor, between Japanese acute coronary syndrome patients and healthy Japanese males
    Nakamura, K.
    Okamoto, H.
    Stringer, F.
    Hirayama, M.
    Nakata, E.
    Minamide, Y.
    Kawamura, M.
    Ogawa, H.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2011, 9 : 107 - 107
  • [6] Population model of the pharmacokinetics and pharmacodynamics of rivaroxaban - an oral, direct Factor Xa inhibitor in healthy subjects
    Mueck, W.
    Becka, M.
    Kubitza, D.
    Voith, B.
    Zuehlsdorf, M.
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2007, 45 (06) : 335 - 344
  • [7] Safety, pharmacokinetics and pharmacodynamics of multiple oral doses of apixaban, a factor Xa inhibitor, in healthy subjects
    Frost, Charles
    Nepal, Sunil
    Wang, Jessie
    Schuster, Alan
    Byon, Wonkyung
    Boyd, Rebecca A.
    Yu, Zhigang
    Shenker, Andrew
    Barrett, Yu Chen
    Mosqueda-Garcia, Rogelio
    LaCreta, Frank
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2013, 76 (05) : 776 - 786
  • [8] Phase 2 study of TAK-442, an oral factor Xa inhibitor, in patients following acute coronary syndrome
    Goldstein, Sidney
    Bates, Eric R.
    Bhatt, Deepak L.
    Cao, Charlie
    Holmes, David
    Kupfer, Stuart
    Martinez, Felipe
    Spaeder, Jeffrey
    Weitz, Jeffrey I.
    Ye, Zhan
    Zannad, Faiez
    THROMBOSIS AND HAEMOSTASIS, 2014, 111 (06) : 1141 - 1152
  • [9] Safety, pharmacokinetics and pharmacodynamics of single/multiple doses of the oral, direct Factor Xa inhibitor rivaroxaban in healthy Chinese subjects
    Zhao, Xia
    Sun, Peihong
    Zhou, Ying
    Liu, Yuwang
    Zhang, Huilin
    Mueck, Wolfgang
    Kubitza, Dagmar
    Bauer, Richard J.
    Zhang, Hong
    Cui, Yimin
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2009, 68 (01) : 77 - 88
  • [10] POPULATION PHARMACOKINETICS AND PHARMACODYNAMICS OF PD 0348292, AN ORAL, DIRECT FACTOR XA INHIBITOR, IN HEALTHY SUBJECTS.
    Xuan, D.
    Boyd, R.
    DiCarlo, L.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2010, 87 : S54 - S55
12345